Prohost Letter #406
A Special Prohost Issue

SYNOPSIS

REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES

VERTEX

Vertex (VRTX): Great news about 2016 revenues & earnings Growth and pipeline.

FROM YESTERDAY: Tremendous Revenues Growth. Cystic fibrosis (CF) revenues grew up around 75%.

FOR TOMORROW:  Boosting  the  pipeline  value  by Advancing CF novel correctors into

Phase 2 trials while Producing and advancing new CF correctors.

PROJECTIONS: Continued revenues and earnings growth in 2017. Progress in . . .